You will be shown a claim related to the COVID-19 pandemic, and the abstract of a biomedical research paper. Each sentence from the abstract will be on a separate line. Your task is to return a JSON object with two fields:

- "verdict": The fact-checking verdict. If the information in the abstract supports the claim, write "SUPPORT". If the abstract contradicts the claim, write "CONTRADICT".
- "evidence": An array of sentences providing evidence for the verdict. Please copy all relevant sentences verbatim from the abstract.

For instance, if the model were given the claim "the COVID vaccine is safe for healthy adults", the output might be
{
  "verdict": "SUPPORT",
  "evidence": ["Our findings indicate that the risks of severe COVID vaccine side effects are low for healthy adults."]
}

Claim: Anakinra to causes respiratory failure in covid-19

Abstract:
Introduction The management of pneumonia caused by SARS-CoV-2 should rely on early recognition of the risk for progression to severe respiratory failure (SRF) and its prevention.
We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.
Methods In this open-label prospective trial, 130 patients admitted with SARS-CoV-2 pneumonia SARS-CoV-2 and suPAR levels [≥]6 g/l were assigned to subcutaneous anakinra 100mg once daily for 10 days.
The primary outcome was the incidence of SRF at day 14.
Secondary outcomes were 30-day mortality, changes in sequential organ failure assessment (SOFA) score, of cytokine-stimulation pattern and of circulating inflammatory mediators.
Equal number of propensity score-matched comparators for comorbidities, severity on admission and standard-of care (SOC) were studied.
Results The incidence of SRF was 22.3% (95% CI, 16.0-30.2%) among anakinra-treated patients and 59.2% (95% CI, 50.6-67.3%; P: 4.6 x 10-8) among SOC comparators (hazard ratio, 0.30; 95%CI, 0.20-0.46).
30-day mortality was 11.5% (95% CI, 7.1-18.2%) and 22.3% (95% CI, 16.0-30.2%) respectively (hazard ratio 0.49; 95% CI 0.25-0.97%; P: 0.041).
Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score.
Duration of stay at the intensive care unit and at hospital was shortened compared to the SOC group; the cost of hospitalization was decreased.
Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro-/anti-inflammatory balance.
{"verdict": "CONTRADICT", "evidence": ["We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.", "Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score.", "Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro-/anti-inflammatory balance."]}